Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 36 publications
Fludarabine and Total Body Irradiation 800 cGy or 1125 cGy For Allogeneic Stem Cell Transplant Using Graft Versus Host Disease Prophylaxis With Post-Transplant Cyclophosphamide and Tacrolimus, Without Mycophenolate Mofetil (OmitMMF trial).
Journal: Transplantation and cellular therapy
Published: June 04, 2026
Pre-vaccine immune profiling in cancer patients identifies correlates of COVID-19 vaccine responses.
Pre-vaccine immune profiling in cancer patients identifies correlates of COVID-19 vaccine responses.
Journal: Human vaccines & immunotherapeutics
Published: December 16, 2025
Single Center Retrospective Comparison of Post-Transplant Cyclophosphamide and Standard Graft-Versus-Host Disease Prophylaxis in Matched Donor Allogeneic Transplantation.
Journal: Transplantation proceedings
Published: October 20, 2025
Irradiated Bone Marrow Volume is Associated With Hematologic Toxicity in Patients With Multiple Myeloma.
Journal: International journal of radiation oncology, biology, physics
Published: May 29, 2024
A Phase I Trial Evaluating the Addition of Lenalidomide to Patients with Relapsed/Refractory Multiple Myeloma Progressing on Ruxolitinib and Methylprednisolone.
Journal: Targeted oncology
Published: March 04, 2024
Low booster uptake in cancer patients despite health benefits.
Journal: medRxiv : the preprint server for health sciences
Published: November 14, 2023
Low booster uptake in cancer patients despite health benefits.
Journal: iScience
Published: October 30, 2023
Does bortezomib influence pre-transplant desensitization therapy or benefit post-heart transplant outcomes for highly sensitized patients?
Journal: Clinical transplantation
Published: July 28, 2023
Progression-Free Survival of Daratumumab Versus Bortezomib Triplet Combination With Lenalidomide and Dexamethasone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma: TAURUS Chart Review Study.
Journal: Clinical lymphoma, myeloma & leukemia
Published: March 31, 2023
Ruxolitinib and methylprednisolone for treatment of patients with relapsed/refractory multiple myeloma.
Journal: British journal of haematology
Published: September 01, 2022
Successful autologous hematopoietic stem cell transplants using Salmonella positive products collected from asymptomatic donors.
Journal: Transfusion
Published: August 26, 2022
A phase 1 study of ruxolitinib, steroids and lenalidomide for relapsed/refractory multiple myeloma patients.
Journal: Hematological oncology
Published: May 06, 2022
Last Updated: 09/26/2026